Cargando…

A VDAC1-Derived N-Terminal Peptide Inhibits Mutant SOD1-VDAC1 Interactions and Toxicity in the SOD1 Model of ALS

Mutations in superoxide dismutase (SOD1) are the second most common cause of familial amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease caused by the death of motor neurons in the brain and spinal cord. SOD1 neurotoxicity has been attributed to aberrant accumulation of misfolded...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shteinfer-Kuzmine, Anna, Argueti, Shirel, Gupta, Rajeev, Shvil, Neta, Abu-Hamad, Salah, Gropper, Yael, Hoeber, Jan, Magrì, Andrea, Messina, Angela, Kozlova, Elena N., Shoshan-Barmatz, Varda, Israelson, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702328/ https://www.ncbi.nlm.nih.gov/pubmed/31474832 http://dx.doi.org/10.3389/fncel.2019.00346

Ejemplares similares

Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS
por: Shteinfer-Kuzmine, Anna, et al.
Publicado: (2022)

VDAC1 at the Intersection of Cell Metabolism, Apoptosis, and Diseases
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2020)

The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link
por: Amsalem, Zohar, et al.
Publicado: (2020)

Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma
por: Shteinfer-Kuzmine, Anna, et al.
Publicado: (2017)

VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor Microenvironment
por: Zerbib, Erez, et al.
Publicado: (2021)

Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks
por: Pandey, Swaroop Kumar, et al.
Publicado: (2022)

Selective induction of cancer cell death by VDAC1‐based peptides and their potential use in cancer therapy
por: Shteinfer‐Kuzmine, Anna, et al.
Publicado: (2018)

Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
por: Arif, Tasleem, et al.
Publicado: (2018)

The Multicellular Effects of VDAC1 N-Terminal-Derived Peptide
por: Anand, Uttpal, et al.
Publicado: (2022)

VDAC1: from structure to cancer therapy
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2012)

Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2021)

VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism
por: Klapper-Goldstein, Hadar, et al.
Publicado: (2020)

VDAC1 and the TSPO: Expression, Interactions, and Associated Functions in Health and Disease States
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2019)

Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo
por: Arif, Tasleem, et al.
Publicado: (2014)

Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo
por: Arif, Tasleem, et al.
Publicado: (2017)

Targeting Liver Cancer and Associated Pathologies in Mice with a Mitochondrial VDAC1-Based Peptide
por: Pittala, Srinivas, et al.
Publicado: (2018)

Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells
por: Arif, Tasleem, et al.
Publicado: (2019)

Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
por: Verma, Ankit, et al.
Publicado: (2022)

4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice
por: Alfahel, Leenor, et al.
Publicado: (2022)

Correction: Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
por: Verma, Ankit, et al.
Publicado: (2023)

VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia
por: Prezma, T, et al.
Publicado: (2013)

MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS
por: Shvil, Neta, et al.
Publicado: (2018)

Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus
por: Pittala, Srinivas, et al.
Publicado: (2020)

Editorial: Uncovering the Function of the Mitochondrial Protein VDAC in Health and Disease: From Structure-Function to Novel Therapeutic Strategies
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

Post-Translational Modification Analysis of VDAC1 in ALS-SOD1 Model Cells Reveals Specific Asparagine and Glutamine Deamidation
por: Pittalà, Maria Gaetana Giovanna, et al.
Publicado: (2020)

Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept
por: Arif, Tasleem, et al.
Publicado: (2019)

Hexokinase I N-terminal based peptide prevents the VDAC1-SOD1 G93A interaction and re-establishes ALS cell viability
por: Magrì, Andrea, et al.
Publicado: (2016)

Apoptotic proteins with non-apoptotic activity: expression and function in cancer
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2023)

Specific Post-Translational Modifications of VDAC3 in ALS-SOD1 Model Cells Identified by High-Resolution Mass Spectrometry
por: Pittalà, Maria Gaetana Giovanna, et al.
Publicado: (2022)

Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells
por: Zhang, Enming, et al.
Publicado: (2019)

Human VDAC pseudogenes: an emerging role for VDAC1P8 pseudogene in acute myeloid leukemia
por: Pappalardo, Xena Giada, et al.
Publicado: (2023)

News about VDAC1 in Hypoxia
por: Mazure, N. M.
Publicado: (2016)

Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression
por: Pandey, Swaroop Kumar, et al.
Publicado: (2022)

VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis
por: Magrì, Andrea, et al.
Publicado: (2018)

Hypoxic-induced truncation of voltage-dependent anion channel 1 is mediated by both asparagine endopeptidase and calpain 1 activities
por: Pahima, Hadas, et al.
Publicado: (2018)

Overexpression of the mitochondrial anti-viral signaling protein, MAVS, in cancers is associated with cell survival and inflammation
por: Trishna, Sweta, et al.
Publicado: (2023)

Boundary Cap Neural Crest Stem Cells Promote Survival of Mutant SOD1 Motor Neurons
por: Aggarwal, Tanya, et al.
Publicado: (2017)

Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
por: Risiglione, Pierpaolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjh10290pek5n1a5irlu6m2jbo